Achieving blood pressure targets with the perindopril/amlodipine combination

Elevated blood pressure (BP) is one of the most important risk factors for cardiovascular (CV) morbidity and mortality, and BP lowering is associated with reduction of coronary events. Despite this, less than one-third of hypertensive patients in Europe have adequate BP control. Improvement of the rates of adequate BP control and thereby a reduction of CV morbidity and mortality, currently represent a major challenge in the daily clinical practice. Many patients require two or more antihypertensives to achieve guideline-recommended BP targets. Findings from different studies have demonstrated that the fixed-dose combination (FDC) perindopril/amlodipine is an effective and well tolerated treatment in patients uncontrolled with monotherapy, and in patients inadequately managed on another combination therapy. The perindopril/amlodipine FDC provides good rates of BP control in daily clinical practice. These good rates of BP control could be ex- plained by the synergistic mode of action of the two components, leading to enhanced BP lowering and reduced side effects, which may have a positive impact on treatment adherence. Krka’s perindopril/amlodipine FDC is available in the full range of doses, providing a flexible and effective treatment of hypertension.